Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Conditions:   Constitutional Mismatch Repair Deficiency Syndrome;   Hematopoietic and Lymphoid Cell Neoplasm;   Lynch Syndrome;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Primary Central Nervous System Neoplasm;   Refractory Lympho ma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Primary Central Nervous System Neoplasm;   Xeroderma Pigmentosum Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials